Get the Stockscreener App
26.59
4.21%
-1.17
Zenas Biopharma Inc stock is traded at $26.59, with a volume of 567.48K.
It is down -4.21% in the last 24 hours and up +34.36% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$27.76
Open:
$29.29
24h Volume:
567.48K
Relative Volume:
2.42
Market Cap:
$1.12B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+22.20%
1M Performance:
+34.36%
6M Performance:
+292.18%
1Y Performance:
+55.95%
1-Day Range:
$25.80
$29.73
1-Week Range:
$18.33
$29.73
52-Week Range:
$5.83
$29.73
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
26.59 | 1.31B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Wedbush | Outperform |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Zenas BioPharma Independent Director Acquires 447% More Stock - simplywall.st
Zenas climbs on licensing deal with InnoCare - MSN
Zenas Biopharma stock hits all-time high at 29.29 USD By Investing.com - Investing.com Canada
Insider Buying: Zenas BioPharma (NASDAQ:ZBIO) Insider Buys 36,928 Shares of Stock - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Director Hongbo Lu Purchases 263,160 Shares - MarketBeat
Fairmount Funds Management Llc Acquires 316,219 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock - MarketBeat
Zenas Biopharma stock hits all-time high at 29.29 USD - Investing.com India
Zenas BioPharma (ZBIO) Is Up 32.5% After Securing Global Rights to Orelabrutinib in MS Deal - Yahoo Finance
Zenas BioPharma (NASDAQ:ZBIO) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Zenas BioPharma Inc Stock Analysis and ForecastSector Rotation Strategies & Watch Expert Picks Before They Rally - earlytimes.in
Will Zenas BioPharma Inc. stock go up soonTrade Entry Summary & Scalable Portfolio Growth Ideas - newser.com
Wedbush Issues Positive Forecast for Zenas BioPharma (NASDAQ:ZBIO) Stock Price - MarketBeat
HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
Zenas BioPharma files automatic mixed securities shelf - MSN
Zenas BioPharma: Strategic Licensing and Clinical Advancements Justify Buy Rating - TipRanks
Rx Rundown: Novo Nordisk, Chiesi Group, Zenas Biopharma and more - Medical Marketing and Media
Zenas Biopharma (ZBIO) director Moulder buys $770k in shares By Investing.com - Investing.com South Africa
InnoCare Pharma: Obutinib signs licensing agreement with Zenas BioPharma - iHeart
Insider Buying Spree: Zenas BioPharma Executives Make Bold Moves! - TipRanks
Zenas Biopharma (ZBIO) director Moulder buys $770k in shares - Investing.com India
Lu Hongbo buys Zenas Biopharma (ZBIO) shares worth $6m - Investing.com
Zenas BioPharma rises after Wedbush raises price target - MSN
Zenas BioPharma hits record high as brokerages raise PT - TradingView
Zenas acquires BTK inhibitor in Phase 3 trials for progressive MS - Multiple Sclerosis News Today
Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal (ZBIO) - Seeking Alpha
H.C. Wainwright maintains Zenas Biopharma stock Buy rating on pipeline expansion - Investing.com Canada
Strategic Expansion and Financial Strength Bolster Zenas BioPharma’s Growth Potential: Buy Rating Reaffirmed - TipRanks
Wedbush Raises Price Target on Zenas BioPharma to $40 From $35, Keeps Outperform Rating - MarketScreener
Risk vs reward if holding onto Zenas BioPharma Inc.Earnings Risk Summary & Expert Curated Trade Ideas - newser.com
Should you wait for a breakout in Zenas BioPharma Inc.July 2025 Retail & Risk Adjusted Swing Trade Ideas - newser.com
Zenas BioPharma (Nasdaq:ZBIO) Secures License for Three Autoimmune Candidates Including Orelabrutinib - Kalkine Media
Why Zenas BioPharma (ZBIO) Jumped 17.1% After Announcing $200M Shelf Filing and Major License Talks - simplywall.st
Zenas BioPharma and InnoCare Pharma Announce License - GlobeNewswire
Zenas Biopharma Inc Files For Mixed Shelf- SEC Filing - TradingView
Zenas Looks To Target Progressive Multiple Sclerosis Via InnoCare Deal - insights.citeline.com
Zenas gets global rights for Innocare BTK inhibitor in $2B+ deal - BioWorld MedTech
Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug - inkl
Zenas BioPharma (NASDAQ:ZBIO) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug - Reuters
Zenas inks license agreement with InnoCare for 3 autoimmune programs - The Pharma Letter
Zenas looks to China to stock pipeline with 3 more immune drugs - BioPharma Dive
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap UpWhat's Next? - MarketBeat
InnoCare Pharma's US Unit Grants Exclusive License of MS Drug to Zenas BioPharma - 富途牛牛
Zenas climbs on licensing deal with InnoCare (ZBIO:NASDAQ) - Seeking Alpha
Zenas Biopharma stock soars after securing rights to MS drug candidate - Investing.com Australia
Zenas BioPharma Secures Licensing Deal with InnoCare - TipRanks
Waltham company forges $2B deal for MS drug - The Business Journals
InnoCare Pharma says unit entered exclusive license agreement & subscription agreement with Zenas BioPharma - MarketScreener
Zenas Biopharma licenses three autoimmune candidates from InnoCare - Investing.com
InnoCare, Zenas sign global licensing pact worth over $2 bln - MarketScreener
Zenas Biopharma Inc Stock (ZBIO) Financials Data
There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Zenas Biopharma Inc Stock (ZBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Oct 07 '25 |
Buy |
19.00 |
316,219 |
6,008,161 |
2,209,025 |
| Lu Hongbo | Director |
Oct 07 '25 |
Buy |
19.00 |
263,160 |
5,000,040 |
321,983 |
| MOULDER LEON O JR | Chief Executive Officer |
Feb 18 '25 |
Buy |
6.67 |
25,000 |
166,750 |
266,155 |
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 04 '24 |
Buy |
9.98 |
45,000 |
449,100 |
241,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 18 '24 |
Buy |
15.00 |
7,500 |
112,500 |
168,655 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):